Publicacións en colaboración con investigadores/as de Hospital General Universitario de Valencia (24)

2024

  1. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

    Archivos de Bronconeumologia

  2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  3. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

  4. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

  5. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

    Lung Cancer, Vol. 195

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 703-711

2021

  1. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry

    PLoS ONE, Vol. 16, Núm. 6 June

  2. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  3. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2363-2376

  4. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

  5. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Development of a multicriteria decision analysis framework for evaluating and positioning oncologic treatments in clinical practice

    Journal of Oncology Practice

  2. Lung cancer symptoms at diagnosis: Results of a nationwide registry study

    ESMO Open, Vol. 5, Núm. 6

  3. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation

    Cancer Epidemiology, Vol. 67

2019

  1. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  2. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

  3. Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

    Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475

2018

  1. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

2017

  1. A consensus statement on the gender perspective in lung cancer

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535